LifeMD, Inc. (LFMD)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
$2.32+4.04%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
Research Workspace
Put LFMD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Revenue growth to $220M-$230M in fiscal 2026: Revenue guidance: $205.5M to $212.5M.
View ThesisRevenue growth is slowing — up about 2% over the past year and decelerating.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 66% in its worst 12-month stretch.
View RiskLFMD’s virtual-care access through AT&T partnerships must support renewed growth. Revenue fell 4% year over year in Q2 FY2026, despite an EPS beat. LFMD trades at 0.6× sales versus a 1.8× peer median, below its own 0.9× historical multiple. The desk says expectations look modest versus its growth view. The thesis is broken because fiscal 2026 revenue guidance of $205.5M to $212.5M falls below the $220M to $230M target. Our model puts the next-quarter miss probability at 36%. Peer multiples imply a price about 67% above where it trades; this read is provisional.
Trailing returns as of 2026-10-29. LFMD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering LFMD (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for LFMD in the last 4 months.
Continue this research
Compare LFMD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LFMD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put LFMD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand virtual care access through exclusive AT&T collaboration
Securing AT&T partnership enhances virtual care access significantly.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $2.32
The last 12 months of price, then the range of analyst 12-month targets from today’s $2.32.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Expand strategic partnerships and product launches in men’s and women’s health
Partnership enhances growth potential in health sector.
Analysts' lower targets indicate potential revenue growth issues.
Advances: Achieve revenue growth to $205.5M-$212.5M in 2026
Confirms patient demand supporting revenue growth.
New CTO appointment supports growth objectives.